| 貨號 | 規(guī)格 | 價格 | 上海 | 北京 | 武漢 | 南京 | 購買數(shù)量 |
|---|---|---|---|---|---|---|---|
S86351-5mg |
≥98% | ￥600.00 | 貨期：2-3天 | - | - | - |
|
S86351-10mg |
≥98% | ￥1080.00 | 貨期：2-3天 | - | - | - |
|
S86351-50mg |
≥98% | ￥3660.00 | 貨期：2-3天 | - | - | - |
|
S86351-100mg |
≥98% | ￥5700.00 | 貨期：2-3天 | - | - | - |
|
Methylnaltrexone, used in form of methylnaltrexone bromide, is one of the newer agents of peripherally-acting μ-opioid antagonists. Methylnaltrexone acts to reverse some of the side effects of opioid drugs such as constipation without affecting analgesia or precipitating withdrawals.
| 產(chǎn)品描述： | Methylnaltrexone, used in form of methylnaltrexone bromide, is one of the newer agents of peripherally-acting μ-opioid antagonists. Methylnaltrexone acts to reverse some of the side effects of opioid drugs such as constipation without affecting analgesia or precipitating withdrawals. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點： | Opioid Receptor;OpioidReceptor | ||||||||||||||||||||
| 參考文獻(xiàn)： | 1. Rauck RL. Treatment of opioid-induced constipation: focus on the peripheral μ-opioid receptor antagonist methylnaltrexone. Drugs. 2013 Aug;73(12):1297-306. doi: 10.1007/s40265-013-0084-5. Review. PubMed PMID: 23881667. 2. Grover M, Camilleri M. Treatment with Methylnaltrexone and IVIG for Paraneoplastic Gastrointestinal Dysmotility. Gastroenterol Hepatol (N Y). 2013 Jan;9(1):51-3. Review. PubMed PMID: 24707236; PubMed Central PMCID: PMC3975980. 3. Bader S, Dürk T, Becker G. Methylnaltrexone for the treatment of opioid-induced constipation. Expert Rev Gastroenterol Hepatol. 2013 Jan;7(1):13-26. doi: 10.1586/egh.12.63. Review. PubMed PMID: 23265145. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存條件： | 2-8℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網(wǎng)安備 31011702002021號
危險品化學(xué)品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京